- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
Schering acquires Japanese rights to MS-325
An agreement reached Jan. 10 gives Schering exclusive rights to codevelop, manufacture, and market Epix Medical's premier vascular agent in Japan. The product, MS-325, is in phase III clinical trials to document its ability to help visualize peripheral
An agreement reached Jan. 10 gives Schering exclusive rights to codevelop, manufacture, and market Epix Medical's premier vascular agent in Japan. The product, MS-325, is in phase III clinical trials to document its ability to help visualize peripheral vascular disease with MRI.
Schering gained worldwide sales and marketing rights to the product, excluding Japan, in June. The terms of the latest deal call for Schering to pay Epix $3 million up front, along with additional milestone payments. Simultaneously with this transaction, Epix reacquired rights to the Japanese market for MS-325 from Daiichi Radioisotope Laboratories. Under terms of that agreement, Epix will pay Daiichi $2.8 million in up-front fees and additional milestone payments. Daiichi will also receive a royalty from Epix on net sales of MS-325 in Japan.
Study Reaffirms Low Risk for csPCa with Biopsy Omission After Negative Prostate MRI
December 19th 2024In a new study involving nearly 600 biopsy-naïve men, researchers found that only 4 percent of those with negative prostate MRI had clinically significant prostate cancer after three years of active monitoring.
Study Examines Impact of Deep Learning on Fast MRI Protocols for Knee Pain
December 17th 2024Ten-minute and five-minute knee MRI exams with compressed sequences facilitated by deep learning offered nearly equivalent sensitivity and specificity as an 18-minute conventional MRI knee exam, according to research presented recently at the RSNA conference.
Can Radiomics Bolster Low-Dose CT Prognostic Assessment for High-Risk Lung Adenocarcinoma?
December 16th 2024A CT-based radiomic model offered over 10 percent higher specificity and positive predictive value for high-risk lung adenocarcinoma in comparison to a radiographic model, according to external validation testing in a recent study.
